Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Director | December 03, 2021 | December 08, 2021 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | December 03, 2021 | December 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date December 03, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 107,807 |
Reported balance
After 2021-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-03 · Other · Acquired 107,807 · Balance 107,807 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 59,253 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 48,554 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 9,819 |
Reported balance
After 2021-12-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-03 · Other · Acquired 9,819 · Balance 9,819 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Family Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,373 |
Reported balance
After 2021-12-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-12-03 · Other · Acquired 7,373 · Balance 7,373 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decedents Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 80,324 |
Reported balance
Holding disclosure · report date 2021-12-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 80,324 |
Filing footnotes · ownership attribution and instrument terms
F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac.
F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 59,253 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 48,554 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein.
F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Family Trust except to the extent of his pecuniary interest therein.
F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decedents Trust except to the extent of his pecuniary interest therein.
Emergent BioSolutions Inc.
Report date December 03, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,018,644 |
Reported balance
After 2021-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-03 · Other · Acquired 3,018,644 · Balance 3,018,644 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 1,659,099 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 1,359,545 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 274,930 |
Reported balance
After 2021-12-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-03 · Other · Acquired 274,930 · Balance 274,930 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El Hibri Family Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 206,434 |
Reported balance
After 2021-12-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-12-03 · Other · Acquired 206,434 · Balance 206,434 F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac. F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decendents Trust except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 1,136,971 |
Reported balance
Holding disclosure · report date 2021-12-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,136,971 |
Filing footnotes · ownership attribution and instrument terms
F1: On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac.
F2: Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 1,659,099 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 1,359,545 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein.
F3: Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El Hibri Family Trust except to the extent of his pecuniary interest therein.
F4: Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decendents Trust except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 3,826 | $58.71 | $224,624.46 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 9 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,018 Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 9,722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,482,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,987 | $58.47 | $408,529.89 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,473,122 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F5 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.54 to $59.25. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestricted Stock Units · Derivative | 9,794 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · derivative · entry 15 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,403 Underlying: Common Stock · 9,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F11 · derivative.exercise_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. F11 · derivative.expiration_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,486 | $57.98 | $144,138.28 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 6 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,480,109 Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 9,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 5 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,482,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 10,369 | $58.24 | $603,890.56 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,472,801 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.96 to $59.08. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Options (Right to Buy) · Derivative | 36,053 | $0.00 Strike: $61.01 | $0.00 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · derivative · entry 14 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,053 Underlying: Common Stock · 36,053 shares Expires 2026-02-25 F10 · derivative.exercise_date: On February 26, 2019, Mr. El-Hibri was granted 36,053 stock options vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantRestricted Stock Units · Derivative | 18,029 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · derivative · entry 13 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,197 Underlying: Common Stock · 18,029 shares Expires not disclosed F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F9 · derivative.exercise_date: On February 26, 2019, Mr. El-Hibri was granted 18,029 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. F9 · derivative.expiration_date: On February 26, 2019, Mr. El-Hibri was granted 18,029 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestricted Stock Units · Derivative | 6,430 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · derivative · entry 12 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,168 Underlying: Common Stock · 6,430 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F8 · derivative.exercise_date: On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. F8 · derivative.expiration_date: On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,566 | $61.01 | $95,541.66 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,483,170 Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 6,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,484,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 10,369 | $59.65 | $618,510.85 |
DisclosureSEC source: 0000899243-19-005313 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,478,306 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.40 to $61.21. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 22:48 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,832 | $69.59 | $1,449,698.88 |
DisclosureSEC source: 0000899243-18-029754 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,670 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.31 to $70.32. Read SEC document |
| November 27, 2018 Filed Feb 21, 2019 00:48 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 20,832 | $0.00 Strike: $13.38 | $0.00 |
DisclosureSEC source: 0000899243-19-004317 · doc4a.xml · derivative · entry 9 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,832 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the SEC on November 28, 2018, which reported the sales of shares of Common Stock only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F7 · derivative.exercise_date: The options vested in three equal installments on March 11, 2014, March 11, 2015 and March 11, 2016. Read SEC document |
| November 27, 2018 Filed Feb 21, 2019 00:48 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,832 | $69.59 | $1,449,698.88 |
DisclosureSEC source: 0000899243-19-004317 · doc4a.xml · nonDerivative · entry 5 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,488,675 F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.31 to $70.32. Read SEC document |
| November 27, 2018 Filed Feb 21, 2019 00:48 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,832 | $13.38 | $278,732.16 |
DisclosureSEC source: 0000899243-19-004317 · doc4a.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,509,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the SEC on November 28, 2018, which reported the sales of shares of Common Stock only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F3 · balance_after: The number of shares of Common Stock directly beneficially owned by the Reporting Person reported on this amended Form 4 gives effect to the sales of Common Stock by the Reporting Person as reported on the Forms 4 filed with the SEC on November 21, 2018 and November 28, 2018, as applicable. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 22:48 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 25,000 | $69.96 | $1,749,000.00 |
DisclosureSEC source: 0000899243-18-029754 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428,502 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.98 to $71.76. Read SEC document |
| November 26, 2018 Filed Feb 21, 2019 00:48 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $13.38 | $0.00 |
DisclosureSEC source: 0000899243-19-004317 · doc4a.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,832 Underlying: Common Stock · 25,000 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the SEC on November 28, 2018, which reported the sales of shares of Common Stock only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F7 · derivative.exercise_date: The options vested in three equal installments on March 11, 2014, March 11, 2015 and March 11, 2016. Read SEC document |
| November 26, 2018 Filed Feb 21, 2019 00:48 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 25,000 | $13.38 | $334,500.00 |
DisclosureSEC source: 0000899243-19-004317 · doc4a.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,513,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the SEC on November 28, 2018, which reported the sales of shares of Common Stock only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F3 · balance_after: The number of shares of Common Stock directly beneficially owned by the Reporting Person reported on this amended Form 4 gives effect to the sales of Common Stock by the Reporting Person as reported on the Forms 4 filed with the SEC on November 21, 2018 and November 28, 2018, as applicable. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 15,173 | $70.03 | $1,062,565.19 |
DisclosureSEC source: 0000899243-18-029546 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,453,502 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.67 to $71.18. Read SEC document |
| November 20, 2018 Filed Feb 21, 2019 00:48 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 15,173 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0000899243-19-004317 · doc4a.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,173 shares Expires 2019-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on November 21, 2018, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F6 · derivative.exercise_date: The options vested in three equal installments on March 12, 2013, March 12, 2014 and March 12, 2015. Read SEC document |
| November 20, 2018 Filed Feb 21, 2019 00:48 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 15,173 | $14.44 | $219,098.12 |
DisclosureSEC source: 0000899243-19-004317 · doc4a.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,503,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on November 21, 2018, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F3 · balance_after: The number of shares of Common Stock directly beneficially owned by the Reporting Person reported on this amended Form 4 gives effect to the sales of Common Stock by the Reporting Person as reported on the Forms 4 filed with the SEC on November 21, 2018 and November 28, 2018, as applicable. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $69.54 | $1,390,800.00 |
DisclosureSEC source: 0000899243-18-029546 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,468,675 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $71.27. Read SEC document |
| November 19, 2018 Filed Feb 21, 2019 00:48 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0000899243-19-004317 · doc4a.xml · derivative · entry 6 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,173 Underlying: Common Stock · 20,000 shares Expires 2019-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on November 21, 2018, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. F6 · derivative.exercise_date: The options vested in three equal installments on March 12, 2013, March 12, 2014 and March 12, 2015. Read SEC document |
| November 19, 2018 Filed Feb 21, 2019 00:48 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,000 | $14.44 | $288,800.00 |
DisclosureSEC source: 0000899243-19-004317 · doc4a.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,508,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · kind: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on November 21, 2018, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 20:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 16,318 | $56.57 | $923,109.26 |
DisclosureSEC source: 0000899243-18-022465 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,488,675 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.50 to $56.86. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 20:25 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $55.50 | $1,110,000.00 |
DisclosureSEC source: 0000899243-18-022465 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504,993 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). Read SEC document |
| July 12, 2018 Filed Jul 17, 2018 00:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,600 | $54.52 | $141,752.00 |
DisclosureSEC source: 0000899243-18-019874 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,524,993 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). Read SEC document |
| July 12, 2018 Filed Jul 17, 2018 00:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 12,400 | $54.50 | $675,800.00 |
DisclosureSEC source: 0000899243-18-019874 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,527,593 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:05 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 15,000 | $53.61 | $804,150.00 |
DisclosureSEC source: 0000899243-18-019754 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,993 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act"). Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 22:49 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001019056-18-000780 · elhibri_4.xml · derivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-05-31 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on May 31, 2019. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestrictive Stock Units · Derivative | 13,237 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-007329 · doc4.xml · derivative · entry 5 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,598 Underlying: Common Stock · 13,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On March 10, 2015, Mr. El-Hibri was granted 39,709 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F4 · derivative.expiration_date: On March 10, 2015, Mr. El-Hibri was granted 39,709 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 3,224 | $51.84 | $167,132.16 |
DisclosureSEC source: 0000899243-18-007329 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,554,993 Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 13,237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007329 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 01:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestrictive Stock Units · Derivative | 9,723 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · derivative · entry 10 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,835 Underlying: Common Stock · 9,723 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F7 · derivative.exercise_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F7 · derivative.expiration_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 01:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,368 | $49.97 | $118,328.96 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,544,980 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 01:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 9,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,547,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 01:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionRestrictive Stock Units · Derivative | 9,794 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · derivative · entry 9 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,558 Underlying: Common Stock · 9,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F6 · derivative.expiration_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 01:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 38,577 | $0.00 Strike: $49.64 | $0.00 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,577 Underlying: Common Stock · 38,577 shares Expires 2025-02-26 F5 · derivative.exercise_date: On February 27, 2018, Mr. El-Hibri was granted 38,577 stock options vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 01:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantRestrictive Stock Units · Derivative | 19,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,352 Underlying: Common Stock · 19,288 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F4 · derivative.expiration_date: On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 01:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,385 | $49.64 | $118,391.40 |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,537,625 Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 01:49 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 9,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-006002 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,540,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 16:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 27,983 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0000899243-17-027619 · doc4.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,983 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The options vested in three equal installments on March 14, 2012, March 14, 2013 and March 14, 2014. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 16:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 27,983 | $42.08 | $1,177,524.64 |
DisclosureSEC source: 0000899243-17-027619 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,530,216 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. F3 · price: The selling price of $42.08 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $41.78 to $42.38, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 16:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 27,983 | $22.03 | $616,465.49 |
DisclosureSEC source: 0000899243-17-027619 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| November 28, 2017 Filed Nov 30, 2017 16:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0000899243-17-027619 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,983 Underlying: Common Stock · 20,000 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The options vested in three equal installments on March 14, 2012, March 14, 2013 and March 14, 2014. Read SEC document |
| November 28, 2017 Filed Nov 30, 2017 16:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $41.59 | $831,800.00 |
DisclosureSEC source: 0000899243-17-027619 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,530,216 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. F2 · price: The selling price of $41.59 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $41.03 to $41.82, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 28, 2017 Filed Nov 30, 2017 16:29 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 20,000 | $22.03 | $440,600.00 |
DisclosureSEC source: 0000899243-17-027619 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. Read SEC document |
| November 14, 2017 Filed Nov 15, 2017 21:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,000 | $40.05 | $801,000.00 |
DisclosureSEC source: 0000899243-17-026353 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,490,216 F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.81 to $40.55. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.